Human Genome Sciences, Inc (HGSI)

[chmcnfunds]

Zacks Reiterates a “Neutral” Rating on Human Genome Sciences (HGSI)
Posted by Tammy Falkenburg on Mar 29th, 2012 // No Comments

Human Genome Sciences (NASDAQ: HGSI)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Thursday. They currently have a $8.25 price target on the stock.

Zacks’ analyst wrote, “Human Genome’s fourth quarter 2011 loss of $0.41 per share was narrower than the year-ago loss of $0.46. The loss narrowed due to higher revenues. An encouraging sign for the company was a substantial improvement in net sales of lupus drug Benlysta in its second full quarter on the market. We believe that sales of the drug, which has blockbuster potential, will increase further in the upcoming quarters. The approval of the drug in additional markets such as the EU and Canada is also encouraging. Moreover, Benlysta is under review in many other countries. The company is also making efforts to expand Benlysta’s label as well as develop other pipeline candidates. However, we prefer to remain on the sidelines until we get visibility that the improvement in Benlysta is sustainable. We retain our Neutral stance on the stock with a target price of $8.25.”

A number of other firms have also recently commented on HGSI. Analysts at Canaccord Genuity initiated coverage on shares of Human Genome Sciences in a research note to investors on Monday. They set a “hold” rating and a $10.00 price target on the stock. Separately, analysts at Collins Stewart reiterated a “neutral” rating on shares of Human Genome Sciences in a research note to investors on Wednesday, March 21st. Finally, analysts at Brean Murray reiterated a “hold” rating on shares of Human Genome Sciences in a research note to investors on Tuesday, February 28th.

Human Genome Sciences traded up 0.06% on Thursday, hitting $7.90. Human Genome Sciences has a 1-year low of $6.51 and a 1-year high of $30.15. The stock has a 50-day moving average of $8.32 and a 200-day moving average of $9.42. The company’s market cap is $1.572 billion.

Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax.
_______________________________________________________
http://zolmax.com/zacks-reiterates-a-neutral-rating-on-human-genome-sciences-hgsi/2457/

HGSI